The greatest impact for your trend will likely be the new
cancer agents that continue to allow treatment to move from inpatient to
outpatient settings.[1]
Addiction
Company: Orexo AB
Date of Approval: July 3, 2013
Treatment for: Opiate Dependence
Date of Approval: July 3, 2013
Treatment for: Opiate Dependence
Zubsolv (buprenorphine and
naloxone) is a sublingual partial opioid agonist indicated for the maintenance
treatment of opioid dependence.
Cancer
Company: Boehringer Ingelheim
Pharmaceuticals Inc.
Date of Approval: July 12, 2013
Treatment for: Non-Small Cell Lung Cancer
Date of Approval: July 12, 2013
Treatment for: Non-Small Cell Lung Cancer
Gilotrif (afatinib) is a kinase
inhibitor indicated for the treatment of patients with metastatic non-small
cell lung cancer (NSCLC).
Company: GlaxoSmithKline
Date of Approval: May 29, 2013
Treatment for: Melanoma - Metastatic
Date of Approval: May 29, 2013
Treatment for: Melanoma - Metastatic
Mekinist (trametinib) is a kinase
inhibitor indicated for the treatment of patients with unresectable or
metastatic melanoma with BRAF V600E or V600K mutations as detected by an
FDA-approved test.
Company: GlaxoSmithKline
Date of Approval: May 29, 2013
Treatment for: Melanoma - Metastatic
Date of Approval: May 29, 2013
Treatment for: Melanoma - Metastatic
Tafinlar (dabrafenib) is a kinase
inhibitor indicated for the treatment of patients with unresectable or
metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved
test.
Cardiovascular
Company: Silvergate Pharmaceuticals Inc.
Date of Approval: August 13, 2013
Treatment for: Hypertension
Date of Approval: August 13, 2013
Treatment for: Hypertension
Epaned (enalapril) is an
angiotensin-converting enzyme inhibitor indicated for the treatment of
hypertension in adults and children older than one month.
Depression
Company: Forest Laboratories, Inc. and
Pierre Fabre Laboratories
Date of Approval: July 25, 2013
Treatment for: Depression
Date of Approval: July 25, 2013
Treatment for: Depression
Fetzima (levomilnacipran) is a
serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the
treatment of major depressive disorder.
·
Forest
Laboratories and Pierre Fabre Laboratories Announce FDA Approval of Fetzima for
the Treatment of Major Depressive Disorder in Adults - July 26, 2013
Company: Osmotica Pharmaceutical Corp.
Date of Approval: July 10, 2013
Treatment for: Depression
Date of Approval: July 10, 2013
Treatment for: Depression
Khedezla (desvenlafaxine) is a
serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the
treatment of major depressive disorder.
- FDA Approves Khedezla for Major Depressive Disorder - July 11, 2013
Endocrine
Lo Minastrin Fe (ethinyl estradiol and
norethindrone, ethinyl estradiol, and ferrous fumarate) Tablets
Company: Warner Chilcott plc
Date of Approval: July 24, 2013
Treatment for: Contraception
Date of Approval: July 24, 2013
Treatment for: Contraception
Lo Minastrin Fe (ethinyl estradiol
and norethindrone, ethinyl estradiol, and ferrous fumarate) is an
estrogen/progestin combined oral contraceptive indicated for use by women to
prevent pregnancy.
Company: Noven Pharmaceuticals, Inc.
Date of Approval: June 28, 2013
Treatment for: Hot Flashes Associated with Menopause
Date of Approval: June 28, 2013
Treatment for: Hot Flashes Associated with Menopause
Brisdelle (paroxetine mesylate) is
a low-dose selective serotonin reuptake inhibitor (SSRI) indicated for the
treatment of moderate to severe vasomotor symptoms associated with menopause.
·
FDA Approves
Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with
Menopause - June 28, 2013
Epilepsy
Company: Supernus Pharmaceuticals, Inc.
Date of Approval: August 16, 2013
Treatment for: Epilepsy
Date of Approval: August 16, 2013
Treatment for: Epilepsy
Trokendi XR (topiramate) is an
antiepileptic drug indicated for the treatment of epilepsy.
Hemophilia
Company: Baxter International Inc.
Date of Approval: June 26, 2013
Treatment for: Hemophilia B
Date of Approval: June 26, 2013
Treatment for: Hemophilia B
Rixubis (coagulation factor IX,
recombinant) is an antihemophilic factor indicated for the control and
prevention of bleeding episodes in adults with hemophilia B.
·
FDA Approves
Rixubis - First Recombinant Coagulation Factor IX For Use in Preventing
Bleeding Episodes - June 27, 2013
HIV Infection
Company: ViiV Healthcare
Date of Approval: August 12, 2013
Treatment for: HIV Infection
Date of Approval: August 12, 2013
Treatment for: HIV Infection
Tivicay (dolutegravir) is an
integrase inhibitor indicated for use in combination with other antiretroviral
(ARV) agents for the treatment of HIV-1.
Organ Transplant
Company: Astellas Pharma US, Inc.
Date of Approval: July 19, 2013
Treatment for: Organ Transplant -- Rejection Prophylaxis
Date of Approval: July 19, 2013
Treatment for: Organ Transplant -- Rejection Prophylaxis
Astagraf XL (tacrolimus) is a
calcineurin-inhibitor immunosuppressant for the prophylaxis of organ rejection
in patients receiving a kidney transplant.
·
Astellas
Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules)
for the Prophylaxis of Organ Rejection - July 22, 2013
Respiratory
Company: GlaxoSmithKline plc (GSK) and
Theravance, Inc.
Date of Approval: May 10, 2013
Treatment for: Chronic Obstructive Pulmonary Disease
Date of Approval: May 10, 2013
Treatment for: Chronic Obstructive Pulmonary Disease
Breo Ellipta (fluticasone and
vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist
(LABA) combination indicated for the treatment of patients with chronic
obstructive pulmonary disease (COPD).
Source: Drugs.com
Posts
No comments:
Post a Comment